Block Grant R43CA126318

This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...

This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Absco Therapeutics, Inc. (DBA Abscotx) to develop an image-guided intratumoral therapy for treating immunotherapy-resistant solid tumors. The project aims to create an innovative drug delivery platform that can improve the efficacy and safety of biologic cancer therapies, addressing challenges such as poor on-target...

The Tiny Cargo Company received a $432,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant to test the scalability of an exosome isolation technology for developing an orally administered radioprotective therapeutic. The goal is to establish proof-of-concept for a safe, orally delivered drug platform capable of transporting biologic and small molecule therapeutics to treat radiation damage and related diseases. The first year of the award will determine scaling...

This Project Grant award from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Targeting Systems to develop a novel intramuscular gene delivery platform capable of sustained expression and endogenous secretion of bispecific natural killer cell engager (BIKE) therapeutics to treat solid tumors like hepatocellular carcinoma. The platform aims to deliver BIKEs in a less invasive manner than current immunotherapies,...

The National Science Foundation Division of Industrial Innovation awarded Theromics Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The award will fund Theromics' STTR PHASE I project titled "THERMAL DIFFUSION STUDIES FOR A TUMOR ABLATION ACCELERANT" from August 1, 2021 to July 31, 2022. The project appears aimed at developing a tumor ablation accelerant through thermal diffusion studies to improve cancer treatment effectiveness. The place of...

The Department of Health and Human Services' National Cancer Institute awarded a $644,034 Project Grant on March 11, 2025 under the Cancer Treatment Research (CFDA 93.395) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant is for the development of a "scintillating nanoparticle drug depot (SCIDD) platform" that uses nanoparticles to convert X-ray energy into light, which can then release potent and tumor-penetrating...

The National Cancer Institute (NCI) awarded a $1,003,173 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Radiopharmaceutical Imaging And Dosimetry, LLC, a company based in Baltimore, Maryland. The funding supports the development of a prototype web/cloud-based quantitative SPECT reconstruction software system for use in clinical trials and ultimately clinical dosimetry for radiopharmaceutical therapy (RPT). The software aims to enable accurate quantitative imaging...

Dexmat, Inc. received a $199,478 Project Grant award from the Department of Energy Office of Science on June 27, 2022 to develop enhanced thermal conductivity carbon nanotube (CNT) fibers under the Office of Science Financial Assistance Program. The Office of Science's mission is to deliver scientific discoveries and major scientific tools to transform our understanding of nature and advance U.S. energy security and economic competitiveness. Under this award, Dexmat will conduct research and...

This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,002,591.00 to Targepeutics, Inc. to determine the intratumoral drug distribution of the immunotoxin GB13 for the treatment of adult and pediatric brain cancers. The 3-year project aims to transform health care for Service Members and the American public through innovative and impactful biomedical research on medical solutions for the battlefield. The...

Federal Grant Award Summary Absco Therapeutics, Inc. (Abscotx) received a $406,500 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) on September 17, 2025, with completion targeted for August 31, 2026. The awardee is developing the Oncolymer platform, an innovative intratumoral delivery system designed to enhance immunotherapy efficacy for solid tumors, particularly microsatellite instability-low cancers such as colorectal carcinoma....